Differential IL-10 receptor gene expression in acute versus chronic atopic eczema.: Modulation by immunosuppressive drugs and cytokines in normal cultured keratinocytes

被引:21
作者
Müschen, A [1 ]
Mirmohammadsadegh, A [1 ]
Jarzebska-Deussen, B [1 ]
Abts, HF [1 ]
Ruzicka, T [1 ]
Michel, G [1 ]
机构
[1] Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany
关键词
atopic eczema; IL-10; receptor; FK506; loratadine; ultraviolet irradiation;
D O I
10.1007/s000110050500
中图分类号
Q2 [细胞生物学];
学科分类号
071009 [细胞生物学]; 090102 [作物遗传育种];
摘要
Objective and Design: The effects of the anticytokine interleukin 10 (IL-10) are mediated by specific receptors. In this study we examined the role of the IL-10 receptor (IL-10R) in the pathophysiology of atopic eczema. Materials and Methods: For this purpose we analyzed the expression of IL-10R in the skin of patients with acute and chronic atopic eczema in comparison to the expression in healthy individuals using in situ binding experiments with fluorescently labeled IL-10 and semiquantitative reverse transcriptase-PCR specific for IL-10R1. In addition, we studied the influence of the Th2-associated cytokine interleukin-4 (IL-4), the Th1-associated gamma-interferon (IFN-gamma), the immunosuppressive drug FK506, the H1-antagonist loratadine and WA irradiation on the expression of IL-10R1 in cultured normal human keratinocytes. Results: We found that IL-10 receptor mRNA and protein are strongly downregulated in acute phase atopic lesions. Furthermore we could show that IL-4, IFN-gamma, FK506, loratadine and UVA enhance the mRNA levels of the IL-10R1 in vitro in normal cultured keratinocytes, We could also demonstrate restored IL-10R1 mRNA levels in lesional atopic skin of a patient after UVA1 therapy, Conclusions: Our results demonstrate for the first time that IL-10 receptors may have a role in the pathogenesis of atopic eczema and its upregulation by FK506 and UVA could explain the therapeutic efficacy of these agents.
引用
收藏
页码:539 / 543
页数:5
相关论文
共 12 条
[1]
[Anonymous], ACTA DERM VENERE S92, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]
[2]
IL-10 is a key cytokine in psoriasis -: Proof of principle by IL-10 therapy:: A new therapeutic approach [J].
Asadullah, K ;
Sterry, W ;
Stephanek, K ;
Jasulaitis, D ;
Leupold, M ;
Audring, H ;
Volk, HD ;
Döcke, WD .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) :783-794
[3]
INTERLEUKIN-10 INHIBITS IGE-MEDIATED NITRIC-OXIDE SYNTHASE INDUCTION AND CYTOKINE SYNTHESIS IN NORMAL HUMAN KERATINOCYTES [J].
BECHEREL, PA ;
LEGOFF, L ;
KTORZA, S ;
OUAAZ, F ;
MENCIAHUERTA, JM ;
DUGAS, B ;
DEBRE, P ;
MOSSALAYI, MD ;
AROCK, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (10) :2992-2995
[4]
BEISSERT S, 1995, J IMMUNOL, V154, P1280
[5]
FIORENTINO DF, 1991, J IMMUNOL, V146, P3444
[6]
A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis [J].
Grewe, M ;
Bruijnzeel-Koomen, CAFM ;
Schöpf, E ;
Thepen, T ;
Langeveld-Wildschut, AG ;
Ruzicka, T ;
Krutmann, J .
IMMUNOLOGY TODAY, 1998, 19 (08) :359-361
[7]
Identification and functional characterization of a second chain of the interleukin-10 receptor complex [J].
Kotenko, SV ;
Krause, CD ;
Izotova, LS ;
Pollack, BP ;
Wu, W ;
Pestka, S .
EMBO JOURNAL, 1997, 16 (19) :5894-5903
[8]
HIGH-DOSE UVA1 THERAPY IN THE TREATMENT OF PATIENTS WITH ATOPIC-DERMATITIS [J].
KRUTMANN, J ;
CZECH, W ;
DIEPGEN, T ;
NIEDNER, R ;
KAPP, A ;
SCHOPF, E .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1992, 26 (02) :225-230
[9]
Michel G, 1997, J IMMUNOL, V159, P6291
[10]
OHMEN JD, 1995, J IMMUNOL, V154, P1956